IKT
Inhibikase Therapeutics Inc
NASDAQ: IKT · HEALTHCARE · BIOTECHNOLOGY
$1.93
-0.52% today
Updated 2026-05-05
Market cap
$254.82M
P/E ratio
—
P/S ratio
10.39x
EPS (TTM)
$-0.49
Dividend yield
—
52W range
$1 – $2
Volume
1.4M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D7.3
Quality
B+3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
13.5
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →197 stocks currently score above 75
Price targets
Analyst target
$6.00
+210.88%
12-Month target
$1.63
-15.54%
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 13.52 — safe zone
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-7.97M
- Revenue declining -100.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $123440.00 | $260500.00 | $0.00 | $0.00 | $1.00 |
| Net income | $-18.05M | $-19.03M | $-27.52M | $-48.26M | $-12.73M |
| EPS | — | — | — | — | $-0.49 |
| Free cash flow | $-17.59M | $-18.10M | $-19.15M | $-27.80M | $-7.97M |
| Profit margin | -14,625.85% | -7,304.75% | — | — | — |
Peer comparison
Smart narrative
Inhibikase Therapeutics Inc trades at $1.93. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 13.52, it sits in the safe zone. TTM revenue stands at $1.00.
Frequently asked questions
What is Inhibikase Therapeutics Inc's stock price?
Inhibikase Therapeutics Inc (IKT) trades at $1.93.
Is Inhibikase Therapeutics Inc overvalued?
Smart Value Score 27/100 (Grade F, Strong Sell).
What is the price target of Inhibikase Therapeutics Inc (IKT)?
The analyst target price is $6.00, representing +210.9% upside from the current price of $1.93.
What is Inhibikase Therapeutics Inc's revenue?
TTM revenue is $1.00.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
13.52 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio10.39x
ROE-36.00%
Beta0.96
50D MA$1.84
200D MA$1.70
Shares out0.13B
Float0.09B
Short ratio—
Avg volume1.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—